This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The interventions were: best supportive care, lamivudine, TDF, adefovir, TDF and lamivudine, entecavir, adefovir and lamivudine, and entecavir and adefovir. Lamivudine was given at 100mg per day, TDF at 300mg per day, adefovir at 10mg per day, and entecavir at 0.5 or 1mg per day. Patients were assumed to receive sequences up to three nucleosides, nucleotides, or combinations. All sequences, except those in which patients were resistant to their third-line treatment before starting it, were considered, giving a total of 211 strategies; for simplicity, only 20 were reported.
Location/setting
UK/out-patient.
Methods

Analytical approach:
The analysis was based on a Markov model with a lifetime horizon. The model considered drug resistance and hepatitis B e antigen (HBeAg)-negative and HBeAg-positive patients. The authors stated that the perspective of the UK NHS was adopted.
Effectiveness data:
A systematic literature review was carried out to identify nucleoside and nucleotide inputs for the model. Additional searches were undertaken to retrieve data on the natural history of CHB. Most of the data on treatment effect and resistance were from a mixed-treatment comparison meta-analysis of RCTs, which synthesised the data to produce the key transition probabilities for the model. Other data were from clinical trials and natural history studies. Some assumptions were required, where there were no published data, particularly for the combination strategies. The key input of the model was drug resistance.
